Reversible cerebral vasoconstriction syndrome due to teprotumumab: two case reports
The temporal correlation between teprotumumab initiation and RCVS's symptom onset raises concern for the potential involvement of teprotumumab in triggering RCVS via disrupting cerebrovascular modulation. Further research is needed to investigate this proposed association.
Authors
- Mohammad Aladawi (ORCID: https://orcid.org/0000-0002-4884-1891)
- Kanchan Kumari (ORCID: https://orcid.org/0000-0001-5463-9764)
- Mithun G. Sattur (ORCID: https://orcid.org/0000-0002-2404-3780)
- Pashayar P. Lookian (ORCID: https://orcid.org/0000-0002-2436-9254)
- Mohamed Elfil (ORCID: https://orcid.org/0000-0002-1125-2946)
- Steven M Phillips
- Mark Jedras
Institutions
- University of Nebraska Medical Center (US)
Publication Details
- Journal
- Oxford Medical Case Reports
- Published
- 2024-08-01
- DOI
- https://doi.org/10.1093/omcr/omae085
- Citations
- 2
- Primary Topic
- Neurological Complications and Syndromes
- Type
- article
- Field-Weighted Citation Impact
- 0.77